A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study.
Alzheimer'S & Dementia (New York, N. Y.)
Hampel, Harald H; Williams, Coralie C; Etcheto, Adrien A; Goodsaid, Federico F; Parmentier, Frédéric F; Sallantin, Jean J; Kaufmann, Walter E WE; Missling, Christopher U CU; Afshar, Mohammad M